Chart-Typ:
Zeitraum:
| T1 Energy Inc.: T1 Energy Reports First Quarter 2025 Results | AUSTIN, Texas and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) ("T1," "T1 Energy," or the "Company") reported financial and operating results for the first quarter 2025 today.... ► Artikel lesen |
| Freyr Battery: Neuer Name, neues Geschäftsmodel - alte Probleme? | Freyr Battery: Neuer Name, neues Geschäftsmodel - alte Probleme ► Artikel lesen |
| FREYR Battery Rebrands as T1 Energy | AUSTIN, Texas & NEW YORK--(BUSINESS WIRE)--FREYR Battery (NYSE: FREY) (or the "Company") is unveiling a strategic rebranding of the Company as T1 Energy Inc. ("T1"). This comprehensive rebrand includes... ► Artikel lesen |
| Niu Technologies Q1 Loss Declines | BEIJING (dpa-AFX) - Niu Technologies (NIU) reported Loss for first quarter of -RMB38.844 millionThe company's earnings totaled -RMB38.844 million, or -RMB0.24 per share. This compares with... ► Artikel lesen |
| Niu Technologies Announces Unaudited First Quarter 2025 Financial Results | -- First Quarter Revenues of RMB 682.0 million, increase 35.1% year over year -- First Quarter Net Loss of RMB 38.8 million, compared to net loss of RMB 54.8 million in the same period of last year... ► Artikel lesen |
| NIU Group erwirbt die Tati-Mine in Botswana und nimmt einen strategischen Bergbau-Standort wieder in Betrieb | Die NIU Group unter der Leitung des österreichischen Investors Cevdet Caner hat die Übernahme und Wiederinbetriebnahme der Tati-Mine in Botswana bekannt gegeben. Damit beginnt für Tati ein neues Kapitel... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease | All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. According to preliminary analysis... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENFIRE RESOURCES LTD finden Sie auf Wallstreet Online.